Last reviewed · How we verify
D: Peg-interferon alpha-2a & Ribavirin
D: Peg-interferon alpha-2a & Ribavirin is a Antiviral combination therapy Small molecule drug developed by Kaohsiung Medical University Chung-Ho Memorial Hospital. It is currently FDA-approved for Chronic hepatitis C virus (HCV) infection. Also known as: PEGASYS, Robatrol.
Pegylated interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis and replication.
Pegylated interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis and replication. Used for Chronic hepatitis C virus (HCV) infection.
At a glance
| Generic name | D: Peg-interferon alpha-2a & Ribavirin |
|---|---|
| Also known as | PEGASYS, Robatrol |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| Drug class | Antiviral combination therapy |
| Target | Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Peg-interferon alpha-2a is a long-acting form of interferon that binds to interferon-alpha receptors on immune cells, triggering antiviral and immunomodulatory effects including upregulation of MHC molecules and activation of natural killer cells. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and depletes guanosine pools, reducing viral replication. Together, they provide synergistic antiviral activity.
Approved indications
- Chronic hepatitis C virus (HCV) infection
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hematologic toxicity (anemia, thrombocytopenia, neutropenia)
- Depression and neuropsychiatric effects
- Thyroid dysfunction
- Injection site reactions
- Headache
Key clinical trials
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment (PHASE1)
- Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders (PHASE2)
- Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1) (PHASE4)
- Ph IIA Study (SOC +/- NS5B) (PHASE2)
- A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D: Peg-interferon alpha-2a & Ribavirin CI brief — competitive landscape report
- D: Peg-interferon alpha-2a & Ribavirin updates RSS · CI watch RSS
- Kaohsiung Medical University Chung-Ho Memorial Hospital portfolio CI
Frequently asked questions about D: Peg-interferon alpha-2a & Ribavirin
What is D: Peg-interferon alpha-2a & Ribavirin?
How does D: Peg-interferon alpha-2a & Ribavirin work?
What is D: Peg-interferon alpha-2a & Ribavirin used for?
Who makes D: Peg-interferon alpha-2a & Ribavirin?
Is D: Peg-interferon alpha-2a & Ribavirin also known as anything else?
What drug class is D: Peg-interferon alpha-2a & Ribavirin in?
What development phase is D: Peg-interferon alpha-2a & Ribavirin in?
What are the side effects of D: Peg-interferon alpha-2a & Ribavirin?
What does D: Peg-interferon alpha-2a & Ribavirin target?
Related
- Drug class: All Antiviral combination therapy drugs
- Target: All drugs targeting Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
- Manufacturer: Kaohsiung Medical University Chung-Ho Memorial Hospital — full pipeline
- Therapeutic area: All drugs in Virology/Infectious Disease
- Indication: Drugs for Chronic hepatitis C virus (HCV) infection
- Also known as: PEGASYS, Robatrol
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing